Open AccessApatinib for advanced nonsmall-cell lung cancer
Author(s) -
C. G. Yang,
Wen Feng,
Di Wu
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_258_17
Subject(s) - apatinib , medicine , common terminology criteria for adverse events , adverse effect , oncology , progressive disease , lung cancer , response evaluation criteria in solid tumors , cancer , tyrosine kinase inhibitor , gastroenterology , disease
Apatinib, a tyrosine kinase inhibitor which selectively inhibits vascular endothelial growth factor receptor-2, has been shown to be beneficial to patients with a variety of cancers, including advanced nonsmall-cell lung cancer (NSCLC). Thus, this study was aimed to retrospectively assess the efficacy and safety of apatinib in patients with advanced/metastatic NSCLC who failed more than two lines of treatment.